http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2537181-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed1cb5a42d2fd56fb866f426a0c759f4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23 |
| filingDate | 2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c85eaeac571c9c6199300f0cac005da1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1ebf0d47531ef2ce7e5955cb62ea12 |
| publicationDate | 2014-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2537181-C2 |
| titleOfInvention | Treating diabetes and metabolic syndrome |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a pharmaceutical composition for intrajejunal administration for reducing an undesirable high serum glucose or reducing undesirable high peak serum insulin, which contains an active compound which is a representative of the calcitonin family, however is not amylin, and which is a modified representative of the calcitonin family, which has an amino acid homology of at least 75% with calcitonin, however not with amylin, and which is modified by adding, substituting or deleting amino acids and preserving an ability to bind and activate a calcitonin receptor, or a non-peptide low-molecular molecule of a calcitonin receptor agonist. n EFFECT: invention enables reducing the undesirable high serum glucose concentration. n 9 cl, 12 dwg, 5 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2699800-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2739255-C2 |
| priorityDate | 2009-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 453.